Athenex, Inc. a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer, visited the Nasdaq MarketSite in Times Square in celebration of its initial public offering (IPO) on The Nasdaq Stock Market.
Athenex aims to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. Athenex has generated its clinical product candidates through its Orascovery and Src Kinase Inhibition research platforms, which are based on the Company’s understanding of human absorption biology and novel approaches to inhibiting kinase activity, respectively.
“We are pleased to have successfully completed our Initial Public Offering on Nasdaq, an exciting milestone in our Company’s growth. We remain focused on developing and commercializing safe and efficacious oncology focused medication and continuing to advance our pipeline candidates through clinical trials,” said Johnson Y.N. Lau, Chief Executive Officer and Board Chairman, Athenex.
“Nasdaq continues to be the listing venue of choice for innovators in both healthcare and technology, two of the fastest changing industries. We welcome Athenex and look forward to supporting the company as it advances novel therapies for cancer treatment and improving health outcomes,” said Nelson Griggs, Executive Vice President, Head of Global Listings, Nasdaq.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Information about the company is provided by the company or comes from the company’s public filings and is not independently verified by Nasdaq. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today’s global capital markets. As the creator of the world’s first electronic stock market, its technology powers more than 89 marketplaces in 50 countries, and 1 in 10 of the world’s securities transactions. Nasdaq is home to 3,800 total listings with a market value of $11.0 trillion.
Read more at //www.stockhouse.com/news/press-releases/2017/06/14/nasdaq-welcomes-athenex-inc-nasdaq-atnx-to-the-nasdaq-stock-market#YM9R9ggCDwEbboIg.99